Neurocrine Biosciences: The Song Remains The Same [Seeking Alpha]
Neurocrine Biosciences, Inc. (NBIX)
Last neurocrine biosciences, inc. earnings: 2/4 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
neurocrine.com/about-us/webcasts-presentations
Company Research
Source: Seeking Alpha
NBIX is projected to reach $4 billion in FY28 sales, supported by a deep pipeline led by MDD candidate osavampator. Trading at 16.4x FY26E EPS and 2.5x FY28 net sales (net cash), NBIX offers an attractive risk-reward profile. I view NBIX as a solid covered call candidate, given strong profitability, pristine balance sheet, and ongoing share repurchases. Looking for a helping hand in the market? Members of The Biotech Forum get exclusive ideas and guidance to navigate any climate. Learn More » koto_feja/E+ via Getty Images Shares of neuroscience therapy concern Neurocrine Biosciences, Inc. ( NBIX have rallied nearly 60% since April 2025 even with a recent pullback, due to solid sales from Ingrezza and no competition for newly launched Crenessity. Despite several clinical trial More on my IG service Live Chat on The Biotech Forum sees frequent discussion of specific covered call trades. To see what covered call trades I am currently executing along with a model portfolio
Show less
Read more
Impact Snapshot
Event Time:
NBIX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NBIX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NBIX alerts
High impacting Neurocrine Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
NBIX
News
- Neurocrine Biosciences Appoints Andrew Ratz, Ph.D., as Chief Technical Operations Officer [Yahoo! Finance]Yahoo! Finance
- Neurocrine Biosciences Appoints Andrew Ratz, Ph.D., as Chief Technical Operations OfficerPR Newswire
- Neurocrine Biosciences (NBIX) had its price target raised by JPMorgan Chase & Co. from $176.00 to $177.00. They now have an "overweight" rating on the stock.MarketBeat
- Neurocrine Biosciences to Present at the Stifel 2026 Virtual CNS ForumPR Newswire
- BetterInvesting™ Magazine Update on Equifax Inc. (NYSE: EFX) and Neurocrine Bio In. (NASDAQ: NBIX)PR Newswire
NBIX
Earnings
- 2/11/26 - Beat
NBIX
Sec Filings
- 3/17/26 - Form 3
- 3/5/26 - Form 4
- 2/23/26 - Form 4
- NBIX's page on the SEC website